Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 15, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Repurchased: 800,000 ordinary shares.
- Repurchase Price: 1,210.29 pence per share.
- Treasury Shares Held: 489,244,158 shares (representing 8.84% of total voting rights).
- Shares in Issue: 5,536,030,667 shares (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the November 15, 2007 transaction. The total number of shares held in Treasury now represents 8.84% of the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,536,030,667) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (489,244,158) and its percentage of total voting rights (8.84%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.